Abiomed
| Formerly | Applied Biomedical Corporation (at founding) |
|---|---|
| Company type | Subsidiary |
| Nasdaq: ABMD | |
| Industry | Medical devices |
| Founded | 1981 |
| Founder | David Lederman |
| Headquarters | Danvers, Massachusetts, U.S. |
Key people | |
| Products | Cardiovascular medical implant devices |
| Revenue | US$1.032 billion (2022) |
| US$140.7 million (2022) | |
| US$136.5 million (2022) | |
| Total assets | US$976.5 million (2022) |
| Total equity | US$1.503 billion (2022) |
Number of employees | 2,003 (2022) |
| Parent | Johnson & Johnson (2022–present) |
| Website | abiomed |
| Footnotes / references | |
Abiomed, Inc. is a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment. Abiomed develops and manufactures temporary external and implantable mechanical circulatory support devices. The company is headquartered in Danvers, Massachusetts with additional offices in Woburn, Baltimore, Berlin, Aachen, and Tokyo.
Andrew Greenfield is President of the company, with Dr. Thorsten Siess as Executive Vice President and Chief Technology Officer and Dr. Chuck Simonton as Executive Vice President and Chief Medical Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients".
As of 2022, the company had secured five FDA approvals and 1,408 patents with 1,416 pending. For fiscal year 2022, Abiomed reported $1.032 billion in revenue and reported diluted earnings per share was $2.98 for the year.
On December 22, 2022, Johnson & Johnson completed the acquisition of Abiomed.